Skip to main content

Pfizer Inc. (PFE) Stock Price & Market Analysis

PFE · NYSE · Pharmaceuticals

Market closedLatest available session print

$27.40

▼ -$0.1400(-0.51%)4:02 PM ET - vs previous close

Quote as of Nov 20, 2026, 4:02 PM EST

Regular-session close · Nov 20, 2026, 4:02 PM EST.

Last session6%
$27.36L Nov 20 '26$28.11H Nov 20 '26
52-week range48%
$23.62$31.44
Long-term rangesAvailable history
Available history(2000-11-22)53%
$5.22L Mar 2 '09$47.09H Dec 20 '21

Historical range: 2000-11-22–2026-11-20. Earlier trading may not be included.

Loading price chart…

Data dates

PriceAt closeLast traded

FundamentalsLast checked

AnalystLast checked

NewsLatest item

What matters next

Next important events

  1. Feb 2, 2027Next earnings (est.)Estimated

Countdown

72 days out

Reported fundamentals

PFE financial overview

Annual revenue

USD 62.58B

Sales for the fiscal year ended Dec 31, 2025. This is not trailing twelve-month revenue.

Revenue change

-1.6%

Change versus the fiscal year ended Dec 31, 2024.

Net profit margin

12.4%

Net income divided by revenue for the fiscal year ended Dec 31, 2025. This is not the trailing margin.

These reported results describe the business’s recent scale and profitability. Compare cash generation and valuation before forming an investment view; historical growth is not a forecast.

Company · ProfileAbout Pfizer Inc. (PFE)Sector, leadership, and how Pfizer Inc. earns its revenue.

Pfizer Inc.

NYSE · PFE · US

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company overview as of Nov 22, 2026.

Sector
Healthcare
Industry
Pharmaceuticals
Headquarters
New York, NY, United States
Country
US
Founded
1849
Employees
75,000
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Exchange
NYSE
Business model & operating resultsExplore business exposure, reported operating measures and the figures behind growth and profitability claims.

Company website ↗

Narrative versus numbers

Demand is expanding

Contradicting observation: -0.4%

Year-over-year growth in the latest quarter. This differs from the fiscal-year revenue change shown above. · Source timestamp: Sep 27, 2026

Growth produces accounting profit

Supporting observation: 6.3%

Net margin; the source did not supply a reporting period. Do not compare this reading with the quarterly or fiscal-year figures above. A positive margin does not establish cash generation. · Source timestamp: Nov 22, 2026, 12:10 AM EST

The business generates cash after investment

Supporting observation: USD 4.8B

Latest free cash flow from the statement feed. It is not a forecast and may cover a different period from the fiscal-year figures above. · Source timestamp: Sep 27, 2026

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Revenue
$16.58Bquarter ended Sep 27, 2026
EPS
$0.56quarter ended Sep 27, 2026
Capital expenditure
$573.00Mquarter ended Sep 27, 2026
Free cash flow
$4.80Bquarter ended Sep 27, 2026
Free cash flow margin
29.0%quarter ended Sep 27, 2026
Operating cash / net income
1.66×quarter ended Sep 27, 2026
Revenue growth year over year
-0.4%quarter ended Sep 27, 2026
Competitors & comparisonsCompare industry peers, reporting periods and related funds. Business mix and valuation bases may differ.
Valuation & fund comparisonsExplore dated peer valuations, growth comparisons and related funds.

Governance & sustainability

Find proxy statements and annual reports

Data sources: Finnhub · SEC Companyfacts · Yahoo Finance

Market data is for information only and is not trading advice. Prices and fundamentals may be delayed, reflect an earlier observation, be incomplete, or be revised. Read the data methodology or the full disclaimer.
Research tools
Market closed

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: 2026-11-23 · 9:30 AM America/New_York

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.